Medical Bulletin 23/July/2026

• Morning Rounds reports on several critical health updates, including the legal and administrative status of service members who refused the Covid-19 vaccine. • The briefing highlights a current Ebola outbreak, which is described as the fastest-growing in history, signaling an urgent public health crisis.

• The FDA is currently reviewing the regulatory status and future of peptides, while companies like RevMed and GSK have received new approvals. • Repligen has expanded its cell therapy capabilities through a $1.5 billion acquisition deal for BioLife.

• A multistate outbreak of cyclosporiasis, a parasite causing severe diarrhea, has spread across 41 U.S. states. • Health officials have linked the surge in cases to contaminated shredded lettuce, with specific mentions of products used at Taco Bell.

• Johns Hopkins Medicine is coordinating with regional public health partners to respond to a cyclosporiasis outbreak in 2026. • The institution is urging immunocompromised individuals who suspect they have the infection to contact their physicians immediately for diagnosis.

• Federal health officials have confirmed a record high of 2,500 cases of cyclosporiasis, a parasitic infection, across the United States. • The Food and Drug Administration (FDA) is currently investigating several additional "subclusters" of cases to identify the source of the outbreak.

• A new study suggests that Vitamin C may help protect the stomach from certain types of cancer. • Researchers identified that coffee, both caffeinated and decaffeinated, may trigger the NR4A1 receptor to provide protective health benefits.

• A Congressional advisory panel has warned that the U.S. is losing its lead in rare disease drug development, labeling the trend a matter of national security. • To combat this, the panel recommends implementing supportive policies, including a finalized FDA platform designation and the adoption of novel trial designs for small patient populations.

• DelveInsight has released a comprehensive analysis of the global Clostridium Difficile Infections (CDI) treatment pipeline projected through 2026. • The report identifies 20 key pharmaceutical companies currently developing 22 distinct therapies to combat the infection.

• Researchers at the Johns Hopkins University Bloomberg School of Public Health published a new study on July 20, 2026, regarding formulary-related insurance denials for single-source branded drugs in the U.S. • The report highlights how drug utilization management tools, such as prior authorization, step therapy, and formulary exclusions, are used to reduce overall drug spending.

• The Indian Health Ministry has approved Qdenga, a new dengue vaccine, following a comprehensive evaluation of its safety, quality, and efficacy. • The approval is based on a pivotal Phase III clinical trial conducted within India, as well as supporting studies from various dengue-endemic nations.

• AI tools utilizing Natural Language Processing (NLP) and Machine Learning (ML) are transitioning from pilot projects to routine use in drug development. • These technologies extract structured clinical data from unstructured Electronic Health Record (EHR) text, such as pathology reports and physician notes.